CCK2R targeting in patients with MTC and other malignancies characterized by CCK2R overexpression using radiolabeled peptide analogs derived from endogenous ligands has high potential for diagnostic and therapeutic application [10,25]. This evidence concerns the gene CCKBR and medullary thyroid gland carcinoma.